BRAIN Biotech AG (HAM:BNN) Current Deferred Taxes Liabilities: € Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BNN BRAIN Biotech AG HAM:BNN
64 GF Score
Price €2.79
GF Value €2.49
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Current Deferred Taxes Liabilities?

BRAIN Biotech AG HAM:BNN -1.08% 64 Current Deferred Taxes Liabilities is € Mil as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 64/100 and a GF Value™ of €2.49 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

BRAIN Biotech AG's current deferred tax liabilities for the quarter that ended in Mar. 2026 was € Mil.

BRAIN Biotech AG Current Deferred Taxes Liabilities Related Terms

BRAIN Biotech AG Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Current Deferred Taxes Liabilities Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BRAIN Biotech AG Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
HAM:BNN
64GF Score
BRAIN Biotech AG HAM:BNN
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of € Mil mean?
BRAIN Biotech AG (HAM:BNN) has a Current Deferred Taxes Liabilities of € Mil as of Mar. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Current Deferred Taxes Liabilities too high?
BRAIN Biotech AG's current Current Deferred Taxes Liabilities is € Mil. Overall, BRAIN Biotech AG has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Current Deferred Taxes Liabilities compare to LIN and SHW?
BRAIN Biotech AG's Current Deferred Taxes Liabilities of € Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Chemicals company?
A good Current Deferred Taxes Liabilities depends on the Chemicals industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Current Deferred Taxes Liabilities is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.49, compared to a current price of €2.79 — trading 12% above its estimated fair value. The current Current Deferred Taxes Liabilities is € Mil. BRAIN Biotech AG's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Current Deferred Taxes Liabilities is € Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.79 is trading 12% above its estimated GF Value™ of €2.49. GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.

Key valuation signals for HAM:BNN:

  • Current Deferred Taxes Liabilities: € Mil
  • GF Value™: €2.49 vs. price of €2.79 (12% above fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
64GF Score

Get the complete analysis for HAM:BNN

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.79
Price
€2.49
GF Value